Overview and Scope
Head and neck cancer therapeutics refer to the various treatment options and
approaches to managing and combating head and neck cancers. The head and neck
cancer therapeutics can benefit from precision of intensity modulated proton
therapy. It also includes efficient therapies such as, surgery, radiation
therapy, chemotherapy, certain medications, and immunotherapy.
Sizing and Forecast
The head and neck cancer therapeutics market size has grown rapidly in recent
years. It will grow from $1.55 billion in 2023 to $1.73 billion in 2024 at a
compound annual growth rate (CAGR) of 11.7%.
The growth in the historic period
can be attributed to tobacco and alcohol consumption, human papillomavirus
(hpv) infections, environmental exposures,
treatment modalities evolution.
The head and neck cancer therapeutics market size is expected to see rapid
growth in the next few years. It will grow to $2.57 billion in 2028 at a
compound annual growth rate (CAGR) of 10.4%.
The growth in the forecast period can be attributed to immunotherapy
advances, precision medicine approaches, awareness and early diagnosis
campaigns, global aging population. Major trends in the forecast period include
expanding role of targeted therapies, adoption of minimally invasive surgical
techniques, integration of palliative care, exploration of novel biomarkers,
patient-centric care models.
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/head-and-neck-cancer-therapeutics-global-market-report
Segmentation & Regional Insights
The head and neck cancer therapeutics market covered in this report is
segmented –
1) By Type: Programmed Cell Death (PD) Inhibitors, Microtubule Inhibitors,
Epidermal Growth Factor Receptor (EGFR) Inhibitors
2) By Route Of Administration: Injectable, Oral
3) By Distribution Channel: Retail And Specialty Pharmacies, Hospital
Pharmacies, Online Pharmacies
4) By Application: Surgery, Radiation Therapy, Chemotherapy, Immunotherapy,
Other Applications
North America was the largest region in the head and neck cancer therapeutics
market in 2023. Asia-Pacific is expected to be the fastest-growing region in
the forecast period. The regions covered in the head and neck cancer
therapeutics market report are
Asia-Pacific, Western Europe, Eastern Europe, North America, South America,
Middle East, Africa
Intrigued to explore the contents? Secure your hands-on sample copy of the
report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12426&type=smp
Major Driver Impacting Market Growth
The increasing prevalence of head and neck cancer is expected to propel the
growth of the head and neck cancer therapeutics market going forward. Head and
neck cancer refers to a disease in which cells start growing uncontrollably in
the tissues of the head and neck region. Increasing cases increase the need for
better diagnosis and treatment to help treat mutations and cancer cell
abnormalities. For instance, in 2023, according to Cancer Research UK, a
UK-based independent cancer research organization, the incidence of head and
neck cancer in the UK is projected to rise by 3% between 2023 and 2025, while
deaths due to head and neck cancers are expected to increase by 12% between
2023 and 2025. Therefore, the increasing prevalence of head and neck cancer is
driving the head and neck cancer therapeutics market.
Key Industry Players
Major companies operating in the head and neck cancer therapeutics market report are Pfizer Inc., F Hoffmann-La
Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi
Aventis LLC, Bristol-Myers-Squibb Company, AstraZeneca PLC, GlaxoSmithKline
plc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead
Sciences Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Teva
Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company
Limited, Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Incyte
Corporation, Ono Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Hikma
Pharmaceuticals PLC, Clinigen Group plc., Ligand Pharmaceuticals, Acceleron
Pharma Inc., Taiho Pharmaceutical Co. Ltd., Boston Biomedical Inc., AB Science
SA.
The head and neck cancer therapeutics market report table of contents includes:
1. Executive Summary
2. Head And Neck Cancer
Therapeutics Market Characteristics
3. Head And Neck Cancer
Therapeutics Market Trends And Strategies
4. Head And Neck Cancer
Therapeutics Market - Macro Economic Scenario
5. Global Head And Neck
Cancer Therapeutics Market Size and Growth
.
32. Global Head And Neck
Cancer Therapeutics Market Competitive Benchmarking
33. Global Head And Neck
Cancer Therapeutics Market Competitive Dashboard
34. Key Mergers And
Acquisitions In The Head And Neck Cancer Therapeutics Market
35. Head And Neck Cancer
Therapeutics Market Future Outlook and Potential Analysis
36. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model:
https://www.thebusinessresearchcompany.com/global-market-model
No comments:
Post a Comment